MS4A1 and primary progressive multiple sclerosis: Anti-CD20 monoclonal antibodies potently reduce MRI lesions and relapses, and slow accumulation of disability in relapsing–remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) (1, 2).